The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care

被引:3
|
作者
Lima, Henrique A. A. [1 ,2 ]
Endo, Yutaka [1 ]
Moazzam, Zorays [1 ]
Alaimo, Laura [1 ]
Dillhoff, Mary [1 ]
Kim, Alex [1 ]
Beane, Joal [1 ]
Ejaz, Aslam [1 ]
Cloyd, Jordan [1 ]
Resende, Vivian [2 ]
Pawlik, Timothy M. M. [1 ]
机构
[1] Ohio State Univ, James Comprehens Canc Ctr, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Fed Univ, Minas Gerais Sch Med, Belo Horizonte, Brazil
关键词
Hepatocellular carcinoma; Medicaid expansion; Difference-in-difference; Surgery; Affordable Care Act; CANCER; MANAGEMENT; DIAGNOSIS; SURVIVAL; VOLUME;
D O I
10.1245/s10434-023-13562-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionThe impact of Medicaid expansion (ME) on hepatocellular carcinoma (HCC) remains controversial, and heterogeneous effects on care processes may relate to sociodemographic factors. We sought to evaluate the association between ME and receipt of surgery in early-stage HCC.MethodsPatients diagnosed with early-stage HCC between 40 and 64 years of age were identified from the National Cancer Database and divided into pre- (2004-2012) and post- (2015-2017) expansion cohorts. Logistic regression was used to identify predictors of surgical treatment. Difference-in-difference (DID) analysis assessed changes in surgical treatment between patients living in ME and non-ME states.ResultsAmong 19,745 patients, 12,220 (61.9%) were diagnosed before ME and 7525 (38.1%) after. Although overall utilization of surgery decreased after expansion (ME, pre-expansion: 62.2% versus post-expansion: 51.6%; non-ME, pre-expansion: 62.1% versus post-expansion: 50.8%, p < 0.001), this trend varied relative to insurance status. Notably, receipt of surgery increased among uninsured/Medicaid patients living in ME states after expansion (pre-expansion: 48.1%, post-expansion: 52.3%, p < 0.001). Moreover, treatment at academic or high-volume facilities increased the likelihood of undergoing surgery before expansion. After expansion, treatment at an academic facility and living in an ME state (OR 1.28, 95% CI 1.07-1.54, p < 0.01) were predictors of surgical treatment. DID analysis demonstrated increased utilization of surgery for uninsured/Medicaid patients living in ME states relative to non-ME states (uninsured/Medicaid: 6.4%, p < 0.05), although no differences were noted among patients with other insurance statuses (overall: 0.7%, private: -2.0%, other: 0.3%, all p > 0.05).ConclusionsImplementation of ME heterogeneously impacted utilization of care in early-stage HCC. Notably, uninsured/Medicaid patients residing in ME states demonstrated increased utilization of surgical treatment after expansion.
引用
收藏
页码:4589 / 4599
页数:11
相关论文
共 50 条
  • [1] The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care
    Henrique A. Lima
    Yutaka Endo
    Zorays Moazzam
    Laura Alaimo
    Mary Dillhoff
    Alex Kim
    Joal Beane
    Aslam Ejaz
    Jordan Cloyd
    Vivian Resende
    Timothy M. Pawlik
    [J]. Annals of Surgical Oncology, 2023, 30 : 4589 - 4599
  • [2] The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care
    Lima, Henrique A. A.
    Endo, Yutaka
    Moazzam, Zorays
    Alaimo, Laura
    Dillhoff, Mary
    Kim, Alex
    Beane, Joal
    Ejaz, Aslam
    Cloyd, Jordan
    Resende, Vivian
    Pawlik, Timothy M. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (08) : 4602 - 4603
  • [3] ASO Author Reflections: The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care
    Lima, Henrique A. A.
    Moazzam, Zorays
    Endo, Yutaka
    Pawlik, Timothy M. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (8) : 4600 - 4601
  • [4] ASO Author Reflections: The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care
    Henrique A. Lima
    Zorays Moazzam
    Yutaka Endo
    Timothy M. Pawlik
    [J]. Annals of Surgical Oncology, 2023, 30 : 4600 - 4601
  • [5] ASO Visual Abstract: The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care
    Henrique A. Lima
    Yutaka Endo
    Zorays Moazzam
    Laura Alaimo
    Mary Dillhoff
    Alex Kim
    Joal Beane
    Aslam Ejaz
    Jordan Cloyd
    Vivian Resende
    Timothy M. Pawlik
    [J]. Annals of Surgical Oncology, 2023, 30 : 4602 - 4603
  • [6] IMPACT OF MEDICAID EXPANSION ON SURGICAL UTILIZATION AMONG PATIENTS WITH EARLY-STAGE HEPATOCELLULAR CARCINOMA
    Lima, Henrique Araujo
    Endo, Yutaka
    Alaimo, Laura
    Moazzam, Zorays
    Dillhoff, Mary
    Ejaz, Aslam
    Cloyd, Jordan
    Pawlik, Timothy M.
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1500 - S1500
  • [7] Evaluating the Impact of Multi-Institutional Care in Early-Stage Hepatocellular Carcinoma: A Nationwide Analysis
    Rasic, Gordana
    Beaulieu-Jones, Brendin
    Chung, Sophie
    Romatowski, Kelsey
    Kenzik, Kelly
    Ng, Sing Chau
    Tseng, Jennifer
    Sachs, Teviah E.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S200 - S200
  • [8] IMPACT OF TRAVEL TIME ON DISPARITIES IN THE TREATMENT OF EARLY-STAGE HEPATOCELLULAR CARCINOMA
    Chyou, Darius
    Jones, Patricia D.
    Goldberg, David S.
    [J]. HEPATOLOGY, 2021, 74 : 389A - 389A
  • [9] Hepatocellular carcinoma: early-stage management challenges
    Erstad, Derek J.
    Tanabe, Kenneth K.
    [J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2017, 4 : 81 - 92
  • [10] Exosomal miRNA in early-stage hepatocellular carcinoma
    Wu, Zhi-Qiang
    Zhu, Yi-Xin
    Jin, Yun
    Zhan, Yin-Chu
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (03) : 528 - 533